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Abstract
Background
Cancers of the head and neck have a high mortality rate, and roughly 10% of the patients
die within six months of diagnosis. To our knowledge little has been written about this group.
We wished to identify risk factors for early death, to predict and monitor patients at risk
better and, if possible, avoid unjustified major treatment.
Methods and findings
This population-based nationwide study from the Swedish Head and Neck Cancer Register
(SweHNCR) included data from 2008–2015 and 9733 patients at potential risk of early
death.
A total of 925 (9.5%) patients died within six months. For every year older the patients
became, the risk of early death increased by 2.3% (p<0.001). The relative risk of death was
3.37 times higher (237%) for patients with WHO score 1 compared with WHO score 0. A pri-
mary tumour in the hypopharynx correlated with a 24% increased risk over the oral cavity
(p<0.024). Patients with stage IV disease had a 3.7 times greater risk of early death than
those with stage I (p<0.001). As expected, a 12 times increased risk of early death was
noted in the palliative treatment group, compared to the curative group.
Limitations to this study were that the actual cause of death was not recorded in the
SweHNCR, and that socioeconomic factors, alcohol consumption, smoking habits, and
HPV status, were not reported in SweHNCR until 2015. However, the fact that this is a
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Conclusions
Identification of patients at increased risk of early death shows that older patients with
advanced disease, increased WHO score, primary tumour in the hypopharynx, and those
given palliative treatment, are more likely than the others to die from head and neck cancer
within six months of diagnosis.
Introduction
Sweden has a population of about 10 million inhabitants, and in 2016 the overall incidence of
cancer was 64 000 in a population of just over 60 000. About 1400 new cases of cancer of the
head and neck are reported annually, and according to the Swedish Cancer Society, this corre-
sponds to 2.3% of all cancers [1]. Cancer of the head and neck is the sixth most common type
worldwide, and most cases (60%) are locally advanced at the time of diagnosis (stage III or IV)
[2]. Many of the tumours are aggressive, and the median survival without treatment is reported
to be three to five months [3–6]. Late stages of the disease are linked to poor overall survival,
but even patients with early cancers (for example of the mobile tongue) can have dismal prog-
noses [7, 8]. The management of metastatic and recurrent cancers of the head and neck is chal-
lenging, and typically involves combined treatments.
Both surgical and oncological treatments usually have acute side effects, but may also result
in long-term consequences, and even death. Apart from our own recent review [9], the issue of
early death (within six months of diagnosis) among patients with cancer of the head and neck
remains poorly explored. Patients with improved survival are often HPV positive, of working
age, and have only a few coexisting conditions, and for these patients reductions in treatment
have been discussed [10, 11]. However, only a few authors have focussed on patients with the
poorest prognosis–the older patients with coexisting conditions and high WHO scores [12,
13]. Treatment-induced side effects [14] [15] can be bearable as long as substantial duration of
survival may be expected, but if it were possible to identify patients for whom it was short,
resources could be more effectively spent on palliative, or at best supportive, care.
The primary aim of this study was to find out which patients were at risk of early death dur-
ing the first six months after diagnosis in a large, nationwide, register-based group of patients
with cancers of the head and neck. Secondly, we wanted to know whether there were any com-
mon denominators that could help identify those patients who were at risk of early death. We
also aimed to increase awareness about this subgroup of patients and achieve our ultimate goal
of improving the management of cancer of the head and neck.
Many studies have dealt with survival but, as far as we know, no population-based studies
have focused on the patients with cancer of the head and neck who die within six months of
diagnosis.
Patients, material, and methods
We obtained our data from the Swedish Head and Neck Cancer Register (SweHNCR) (Ethics
Committee approval; Gothenburg, number 299–14, T230-17), which is funded by the Swedish
government, and covers 98.5% of all Swedish patients with cancers of the head and neck, when
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cross-referenced with Sweden’s National Board of Health and Welfare [16]. The total number
of consecutive affected Swedish patients during the period 2008–2015 in the SweHNCR with
one-year follow-up was 9733 (Fig 1, Table 1).
Nine sites of tumours were included: lip (C00.0–2, C00.6, C00.8, C00.9), oral cavity (C00.3,
C00.4, C02, C03, C04, C05, C06), oropharynx (C01.9, C05.1, C05.2, C05.8, C05.9, C09, C10),
nasopharynx (C11), hypopharynx (C12, C13), larynx (C10.1, C32), nose (C30.0) and nasal
sinuses (C31), salivary glands (C07, C08), and head and neck cancer of unknown primary
(C77.0), Table 1. Malignant tumours located in the thyroid, the parathyroid glands, or the
oesophagus were not included. Data that are reported to SweHNCR include: incidence,
Fig 1. Flow chart for treatment and early death for included patients.
https://doi.org/10.1371/journal.pone.0223154.g001
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Table 1. Prevalence.
Prevalence n (%) Total number = 9733
Diagnosis
Lip 863 (8.9)
Oral cavity 2714 (27.9)
Oropharynx 2524 (25.9)
Nasopharynx 234 (2.4)
Hypopharynx 455 (4.7)
Larynx 1300 (13.4)
Nose/sinuses 477 (4.9)
Salivary glands 795 (8.2)
CUP� 355 (3.6)
Incomplete diagnosis 16 (0.2)
Sex
Male 6244 (64.2)
Female 3489 (35.8)
Age continuous (mean (sd)) 66.8 (13.3)
Age groups
0–39 295 (3.0)
40–49 644 (6.6)
50–59 1751 (18.0)
60–69 3165 (32.5)
70–79 2217 (22.8)
80- 1661 (17.1)
Stage
I 2564 (26.3)
II 1638 (16.8)
III 1265 (13.0)
IV 3711 (38.1)
Missing 200 (2.1)
(CUP lacks stage) 355 (3.6)
WHO score
0 6223 (63.9)
1 1279 (13.1)
2 608 (6.2)
3 344 (3.5)
4 133 (1.4)
Missing 1146 (11.8)
Treatment intent
Curative 8751 (89.9)
Palliative 882 (9.0)
Missing 100 (1.0)
Given treatment
Surgery 2370 (24.4)
Surgery+postoperative RT�� 1295 (13.3)
Preoperative RT+ Surgery 306 (3.1)
Surgery +RT 356 (3.7)
RT 2625 (27.0)
CRT��� 1169 (12.0)
(Continued)
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diagnosis, time to treatment, sex, age, survival, WHO score, TNM classification, stage, follow
up, and recurrence. The Eastern Cooperative Oncology Group score, also called the WHO
score runs from 0 to 5, with 0 denoting perfect health and 5 death [17]. The WHO score was
rated 0–4, Table 2, indicating the physical performance of the patient. An overall increase in
incidence of 22% was noted from 2008 (n = 1211) to 2015 (n = 1473) for head and neck cancer
in Sweden, which corresponds to a yearly increase of 2.9% [16].
Treatment of these cancers in Sweden is centralised to the university hospitals, but a few
second-level hospitals are able to give oncological treatment, and National Healthcare and
Social Security systems are offered equally to all inhabitants. All patients were examined by
either a head and neck surgeon or an oncologist after completion of treatment to evaluate its
efficacy.
Statistical methods
The primary outcome in this study was early death. The relative risk of death within 6 months
of diagnosis between different groups was estimated using univariable and multivariable Pois-
son regression [18]. Robust variance estimates were used with Poisson models to obtain valid
confidence intervals. No censuring occurred within the first 12 months. Observed survival was
calculated using the Kaplan-Meier method [19]. Survival time was calculated from date of
diagnosis to date of death if death occurred before 24 months of diagnosis, censored 24
months of diagnosis or earlier if end of follow-up. The patients were diagnosed in the period
2008 to June 2015 and had a follow-up until June 2016. In the survival analyses, showing prob-
ability of survival for patients with HNC based on treatment intent, tumour site, and treatment
modality (Figs 2–4), patients diagnosed after June 2014 were censored at end of follow-up
before reaching a 24 months follow-up if they still lived. To perform tests of differences in age,
stage and WHO score between patients dead within 0–6 months, and 7–12 months compared
to those alive after 12 months (Table 3), the two-sample t-test and a nonparametric test for
Table 1. (Continued)
Prevalence n (%) Total number = 9733
Other 818 (8.4)
No treatment 245 (2.5)
Missing 549 (5.6)
�CUP = Cancer of unknown primary
��RT = Radiotherapy
���CRT = Chemoradiotherapy
https://doi.org/10.1371/journal.pone.0223154.t001
Table 2. WHO score.
Grade Explanation of activity
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary
nature, e.g., light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than
50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
https://doi.org/10.1371/journal.pone.0223154.t002
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trend across ordered groups developed by Cuzick [20] were used. Exact binominal confidence
intervals were estimated for proportions [21]. A p-value of< 0.05 was considered to be statisti-
cally significant. All statistical analyses were performed using Stata 15.1 [22].
Results
The risk for death within six months has been divided into patient-, tumour and treatment-
related factors. Of the whole group of 9733 patients, 925 died within six months of diagnosis
(9.5%). Among the 9633 patients with a treatment decision at a multidisciplinary tumour
board meeting, 9.1% died within six months, leaving a high rate of early death among patients
for whom details of treatment were missing (n = 51, 51%) (Fig 1).
Patient-related factors
Sex: 6244 patients were male and 3489 female, Table 1. There was no significant survival differ-
ence between sexes where 589 men (9.4%) and 336 women (9.6%), died within six months of
diagnosis (p = 0.75), Table 4.
Age: the mean (range) age at diagnosis was 67 (8–102) years, and the risk to die within six
months after diagnosis increased with older age, Table 3, and with 2.3% for every year older
the patient became (p<0.001), Tables 5 and 6.
Fig 2. Probability of survival for patients with HNC based on treatment intent.
https://doi.org/10.1371/journal.pone.0223154.g002
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WHO score: only 147 patients (2.4%) with a WHO score of 0 died within 6 months, com-
pared with 166 of patients (13%) with a WHO score of 1. Of 133 patients with a WHO score of
Fig 4. Probability of survival based on treatment modality.
https://doi.org/10.1371/journal.pone.0223154.g004
Table 3. WHO/Stage and survival during the first year after diagnosis.
Patients dying within: Alive 12 months after diagnosis
0–6 months p-value� 7–12 months p-value�
Age at diagnosis, years; mean (SD) 75.7 (11.1) <0.001 71.8 (12.2) <0.001 65.3 (13.1)
WHO <0.001 <0.001
0 147 (15.9) 333 (41.0) 5743 (71.8)
1 166 (18.0) 161 (19.8) 952 (11.9)
2 158 (17.1) 130 (16.0) 320 (4.0)
3 167 (18.0) 63 (7.8) 114 (1.4)
4 107 (11.6) 15 (1.8) 11 (0.1)
Unknown 180 (19.5) 111 (13.6) 855 (10.7)
Stage; n (%) <0.001 <0.001
I 52 (5.6) 64 (7.9) 2448 (30.6)
II 70 (7.6) 101 (12.4) 1467 (18.4)
III 124 (13.4) 119 (14.6) 1022 (12.8)
IV 587 (63.5) 477 (58.7) 2647 (33.1)
Missing 92 (10.0) 52 (6.4) 411 (5.1)
�p-value for dead within 6 months as compared to those alive after 12 months
https://doi.org/10.1371/journal.pone.0223154.t003
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Table 4. Univariate analysis, targeted variable is death within 6 months.
Variable Dead within 6 months/N Dead within 6 months % (95% KI) RR (95% KI) P�
Diagnosis
Lip 22/863 2.5 (1.6–3.8) 0.23 (0.15–0.36) <0.001
Oral Cavity 298/2714 10.9 (9.8–12.2) 1.0 -
Oropharynx 217/2524 8.6 (7.5–9.8) 0.78 (0.66–0.92) 0.004
Nasopharynx 10/234 4.3 (2.1–7.7) 0.39 (0.21–0.72) 0.003
Hypopharynx 106/455 23.3 (19.5–27.5) 2.12 (1.74–2.59) <0.001
Larynx 105/1300 8.1 (6.6–9.7) 0.74 (0.59–0.91) 0.005
Nose/Sinuses 66/477 13.8 (10.9–17.3) 1.26 (0.98–1.61) 0.068
Salivary Gland 51/795 6.4 (4.8–8.3) 0.58 (0.44–0.78) <0.001
CUP 46/355 13.0 (9.6–16.9) 1.18 (0.88–1.58) 0.263
Sex
Men 589/6244 9.4 (8.7–10.2) 1.0 -
Women 336/3489 9.6 (8.7–10.7) 1.02 (0.90–1.16) 0.750
Age (continuously) 925/9733 9.5 (8.9–10.1) 1.06 (1.05–1.06) <0.001
Age groups
0–39 0/295 0.0 (0.0–1.2) - -
40–49 10/644 1.6 (0.7–2.8) 0.44 (0.23–0.85) 0.015
50–59 62/1751 3.5 (2.7–4.5) 1.0 -
60–69 226/3165 7.1 (6.3–8.1) 2.02 (1.54–2.67) <0.001
70–79 266/2217 12.0 (10.7–13.4) 3.39 (2.59–4.44) <0.001
80- 361/1661 21.7 (19.8–23.8) 6.14 (4.73–7.97) <0.001
Stage
I 52/2564 2.0 (1.5–2.7) 1.0 -
II 79/1638 4.3 (3.3–5.4) 2.11 (1.48–3.00) <0.001
III 124/1265 9.8 (8.2–11.6) 4.83 (3.52–6.63) <0.001
IV 587/3711 15.8 (14.7–17.0) 7.80 (5.90–30.3) <0.001
WHO score
0 147/6223 2.4 (2.0–2.8) 1.0 -
1 166/1279 13.0 (11.1–14.9) 5.49 (4.44–6.80) <0.001
2 158/608 26.0 (22.5–29.7) 11.0 (8.93–13.6) <0.001
3 167/344 48.5 (43.2–54.0) 20.6 (16.9–24.9) <0.001
4 107/133 80.5 (72.7–86.8) 34.1 (28.4–40.8) <0.001
Unknown 180/1146 15.7 (13.6–18.0) 6.65 (5.40–8.19) <0.001
Treatment intention
Curative 396/8751 4.5 (4.1–5.0) 1.0 -
Palliative 478/882 54.2 (50.8–57.5) 12.0 (10.7–13.4) <0.001
Given treatment
Surgery only 82/2370 3.5 (2.8–4.3) 1.0 -
Surgery+postoperative RT�� 24/1295 1.8 (1.2–27.4) 0.54 (0.34–0.84) 0.007
Preoperative RT+surgery 3/306 1.0 (0.2–2.8) 0.28 (0.09–0.89) 0.031
Surgery+RT 5/356 1.4 (0.5–3.3) 0.41 (0.17–0.99) 0.049
RT only
RT+Chemotherapy
300/2625
43/1169
11.4 (10.2–12.7)
3.7 (2.7–4.9)
3.30 (2.60–4.19)
1.06 (0.74–1.53)
<0.001
0.741
Other treatment 38/818 4.8 (3.4–6.5) 1.34 (0.92–1.96) 0.125
No treatment 169/245 52.4 (48.9–55.9) 13.7 (10.9–17.3) <0.001
�P-value is for Relative Risk
��RT = radiotherapy
https://doi.org/10.1371/journal.pone.0223154.t004
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4, 107 died within 6 months (80.5%). The relative risk of death was 3.37 times higher for
patients with a WHO score of 1 (237%) compared with those who scored 0, Table 6.
Tumour-related factors
Site: the probability of survival varied depending on the site of the primary tumour (Fig 3).
The worst prognosis was found among patients with hypopharyngeal cancer, of whom 106
died within six months (23%), Table 4. Patients with hypopharyngeal cancers had an increased
relative risk for early death of 1.24 compared with those with cancer of the oral cavity
(p = 0.024), Table 6.
Salivary gland cancer is morphologically considered to be a separate entity of head and
neck cancer. Therefore, we performed analyses excluding salivary gland cancer in order to
evaluate differences in risk of death within six months. The exclusion of salivary gland cancer
did not significantly affect the outcome, Tables 6 and 7.
Table 5. Multivariable analysis, targeted variable is death within 6 months (n = 9098).
Curative and palliative treatment
(n = 9098)
Curative treatment
(n = 8314)
Variable RR (95% CI) P� RR (95% CI) P�
Diagnosis
Lip 0.76 (0.49–1.19) 0.227 0.69 (0.41–1.17) 0.167
Oral Cavity 1.0 - 1.0 -
Oropharynx 0.96 (0.82–1.13) 0.645 0.91 (0.68–1.20) 0.500
Nasopharynx 0.61 (0.33–1.12) 0.109 0.38 (0.09–1.52) 0.171
Hypopharynx 1.24 (1.03–1.50) 0.024 1.27 (0.90–1.78) 0.179
Larynx 1.09 (0.89–1.33) 0.424 1.09 (0.81–1.47) 0.583
Nose/Sinuses 0.94 (0.75–1.19) 0.624 1.02 (0.66–1.58) 0.930
Salivary Gland 0.59 (0.45–0.79) <0.001 0.63 (0.41–0.99) 0.046
Sex
Men 1.0 - 1.0 -
Women 0.96 (0.85–1.09) 0.518 0.81 (0.65–1.01) 0.060
Age (continuous) 1.023 (1.017–1.029) <0.001 1.039 (1.029–1.049) <0.001
Stage
I 1.0 - 1.0 -
II 1.68 (1.17–2.40) 0.005 1.59 (1.03–2.48) 0.030
III 2.82 (2.02–3.93) <0.001 3.22 (2.14–4.85) <0.001
IV 3.71 (2.71–5.10) <0.001 4.61 (3.17–6.70) <0.001
WHO score
0 1.0 - 1.0 -
1 3.37 (2.67–4.25) <0.001 3.25 (2.45–4.31) <0.001
2 4.53 (3.54–5.80) <0.001 4.82 (3.51–6.62) <0.001
3 5.68 (4.40–7.32) <0.001 8.29 (5.92–11.6) <0.001
4 6.77 (5.22–8.78) <0.001 16.8 (10.4–21.4) <0.001
unknown 3.47 (2.73–4.40) <0.001 3.08 (2.25–4.23) <0.001
Treatment intention
Curative 1.0 -
Palliative 3.16 (2.68–3.72) <0.001
�P-value is for relative risk
https://doi.org/10.1371/journal.pone.0223154.t005
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Stage: we found an association between tumour stage and the risk of death within six
months, Table 4. Among the 925 patients who died within six months, 587 had stage IV disease
(64%), and only 52 patients (6%) who died within six months had stage I tumours. The distri-
bution between tumour stages also varied depending on the site of the primary tumour with
for example, 699 of all cancers of the lip (81%) being stage I, and only 17 (2%) stage IV. Stage
IV disease was found at diagnosis in two-thirds of patients with oropharyngeal (n = 1691,
67%) and hypopharyngeal (n = 305, 66%) cancers. Most of the 152 patients with nasopharyn-
geal cancer (65%) were diagnosed with stage III or IV disease. In total, a patient with stage IV
disease had a 3.7 times higher relative risk of death within six months than patients with stage
I disease (p<0.001), Table 6.
TNM class.
T: low T class correlated with a better prognosis. Only 77 patients with a T1 tumour (2.4%)
died within six months, while the six-month mortality among T4 patients was 455 (23%).
N: 5777 of patients (59%) had no neck metastases, whereas 3791 did (39%). Data about N
class were missing in 2% of patients. A total of 399 patients with N negative necks (7%) died
within six months, as did 482 patients (13%) with N positive necks.
Table 6. Multivariate analysis, targeted variable is death within 6 months, including all tumour sites (n = 9098).
Variable RR (95% CI) P�
Diagnosis
Lip 0.76 (0.49–1.19) 0.227
Oral Cavity 1.0 -
Oropharynx 0.96 (0.82–1.13) 0.645
Nasopharynx 0.61 (0.33–1.12) 0.109
Hypopharynx 1.24 (1.03–1.50) 0.024
Larynx 1.09 (0.89–1.33) 0.424
Nose/Sinuses 0.94 (0.75–1.19) 0.624
Salivary Gland 0.59 (0.45–0.79) <0.001
Sex
Men 1.0 -
Women 0.96 (0.85–1.09) 0.518
Age (continuous) 1.023 (1.017–1.029) <0.001
Stage
I 1.0 -
II 1.68 (1.17–2.40) 0.005
III 2.81 (2.01–3.92) <0.001
IV 3.74 (2.71–5.13) <0.001
WHO score
0 1.0 -
1 3.37 (2.67–4.25) <0.001
2 4.53 (3.54–5.80) <0.001
3 5.68 (4.40–7.32) <0.001
4 6.77 (5.22–8.78) <0.001
unknown 3.47 (2.73–4.40) <0.001
Treatment intention
Curative 1.0 -
Palliative 3.16 (2.68–3.72) <0.001
�P-value for relative risk of death within 6 months
https://doi.org/10.1371/journal.pone.0223154.t006
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M: Of patients without distant metastases 753 (8%) died within six months. A total of 256
patients (3%) had distant metastasis at the time of diagnosis, and of these 125 (49%) died
within six months.
Treatment-related factors
Curative compared with palliative intent. Treatment with curative intent was recom-
mended to 8751 patients (90.8%), and palliative treatment to 882 (9.2%) (Fig 2). Among those
whose treatment was potentially curative, 396 (4.5%) died within six months (Fig 1, Table 4).
Risk of early death increased among patients with curative treatment decision and high WHO
score and/or high stage, Table 5. Of those for whom palliative treatment or “best supportive
care” was recommended, 478 died within six months (54.2%). During the period 2008–2014
where 8271 patients were studied and a two-year follow up was available interestingly 104
patients (14%) for whom palliative treatment had been recommended survived for more than
two years.
Treatment: Modality. A total of 2370 patients (24%) were treated by primary surgery
alone, and primary surgery was combined with postoperative radiotherapy (RT) in 1295 (16%)
(Fig 4).
In the group who had primary surgery alone, 82 (3.5%) died within six months. When it
was combined with postoperative RT, 24 (1.8%) died within six months. Preoperative RT or
chemoradiotherapy (CRT) together with surgery resulted in the death of eight patients (1%)
Fig 3. Probability of survival based on site of tumor.
https://doi.org/10.1371/journal.pone.0223154.g003
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within six months. Patients given either RT or CRT alone had a mortality of 343 within six
months (9%), Table 4.
Treatment: Outcome. Patients in whom locoregional control was achieved after primary
treatment had a low risk of early death, and only 52 died within six months (0.7%). Among
those for whom primary treatment failed, 381 (35%) died within six months. For a total of
1236 patients (12.7%), data about locoregional control after treatment were missing, and for
these patients the mortality was 493 within six months (40%).
Patient–tumour, and treatment-related factors. Taken together, patient-, tumour and
treatment- related factors all influenced the risk of death within six months. In order to clarify
the extent of how vastly it affects this risk, a comparison between a low-risk patient (55-year
old, oral cavity cancer, WHO 0, stage 1, curative treatment) and a high-risk patient (75-year
old, hypohryngeal cancer, WHO 2, stage III, curative treatment) was made and showed a 24.9
fold risk increase to die within six months for the high-risk patient (95% CI: 16.3–38.0,
p<0.001). If the low-risk patient however, had a stage III disease instead of stage I, the risk of
early death was still 8.8 times higher for the 75-year old man (95% CI: 6.47–12.06, p<0.001).
Recurrence. A total of 8437 of the patients (87%) had no recurrence within the first 12
months.
Table 7. Multivariate analysis, targeted variable is death within 6 months, excluding salivary gland cancer
(n = 8332).
Variable RR (95% CI) P�
Diagnosis
Lip 0.77 (0.49–1.21) 0.255
Oral Cavity 1.0 -
Oropharynx 0.97 (0.83–1.13) 0.663
Nasopharynx 0.60 (0.33–1.11) 0.103
Hypopharynx 1.24 (1.03–1.50) 0.023
Larynx 1.09 (0.89–1.34) 0.383
Nose/Sinuses 0.94 (0.75–1.19) 0.619
Sex
Men 1.0 -
Women 0.99 (0.87–1.12) 0.863
Age (continuous) 1.022 (1.016–1.028) <0.001
Stage
I 1.0 -
II 1.75 (1.21–2.52) 0.003
III 2.88 (2.05–4.07) <0.001
IV 3.72 (2.68–5.16) <0.001
WHO score
0 1.0 -
1 3.40 (2.68–4.31) <0.001
2 4.55 (3.54–5.86) <0.001
3 5.59 (4.30–7.26) <0.001
4 6.48 (4.96–8.45) <0.001
unknown 3.41 (2.66–4.37) <0.001
Treatment intention
Curative 1.0 -
Palliative 3.28 (2.77–3.88) <0.001
�P-value is for relative risk
https://doi.org/10.1371/journal.pone.0223154.t007
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Discussion
Studies on the incidence and aetiology of early death among patients with cancers of the head
and neck are still scarce, and to our knowledge this is not only the first official report to
describe the SweHNCR data on 9733 such patients, but also the first attempt in Europe to
investigate early death among patients in a nationwide population-based series. A previous
Swedish study based on the data from 6785 such patients during the period 2008–2013 indi-
cated a risk of death within six months of 665 (9.8%) [9]. In the present study we found a
slightly reduced risk of early death of 925/9733 patients during the extended period 2008–2015
(9.5%). If data from the group who were given palliative treatment were excluded, the remain-
der (those given curative treatment) had a six-month mortality of 396 (4.5%). Our results sug-
gest that extra precautions should be taken for patients with tumours located in the
hypopharyngeal area, stage IV disease, older age, and increased WHO score.
Five-year mortality from cancers of the head and neck is high, even though mortality in
general has decreased in Northern Europe. One reason for this is the increase in the number of
HPV-induced tumours [23, 24]. Patients in the SweHNCR have an overall relative five-year
survival rate of 6521 (67%), which includes all sites [16]. It has been reported that patients with
early stage cancers of the head and neck can have five-year survival rates of up to 80%, whereas
those with late-stage disease have reduced five-year survival of about 20% [25]. Early mortality
(within six months of diagnosis) has been studied in other cancers [26, 27] but to our knowl-
edge still remains unexplored for the head and neck.
Our results indicate that the risk of early death was associated with patient- related and
treatment-related factors as well as tumour-related ones. Eskiizmir et al in 2017 showed differ-
ences in survival by sex in early-stage laryngeal cancer [21], but we could not confirm a sex dif-
ference in stage I-II laryngeal cancer in our series as 336 (9.6%) women and 590 (9.4%) men
died within six months (p = 0.518).
Our results showed that older patients with cancers of the head and neck had a poorer prog-
nosis than younger ones, and that the risk of early death increased with older age. Other
authors have also found that mortality increases for older patients after resection and CRT [22,
23]. A Danish study by Johansen et al, found that survival improved from 1980 to 2012 for all
age groups up to 79 years of age, but this effect was less pronounced for patients over 80 [24].
Prediction of survival among older patients must be based on available demographic informa-
tion, and the details that are recorded differ among countries. We found a total of 1661
patients over 80 years old, of whom 361 (22%) died within six months. Multivariate analysis
showed that patients over 80 were more likely to have coexisting conditions, but up to 75 years
of age most patients who had a WHO score of 0–1 were less likely to die early. Older patients
with cancer given curative treatment, therefore, should be particularly carefully monitored to
minimise complications and failure of treatment, and ultimately, the risk of early death.
A high WHO score has been reported to be an indicator of a poor prognosis in both leukae-
mia and colon cancer [25, 26]. A total of 107 patients with cancer of the head and neck and a
WHO score of 4 (80.5%) died within six months, Table 4. Among patients who had a WHO
score of 4, 109 (82%) were given palliative treatment because of the severity of their disease, or
coexisting conditions, or both.
Cancers of the head and neck are a heterogeneous group of malignancies with varied biol-
ogy. The aggressiveness of the tumour, coexisting conditions, and presenting symptoms can
all affect the outcome. For example, patients who presented with easily-detected symptoms
such as those of lip cancer (801 of 836 tumours (93%) were diagnosed in stages I-II) or laryn-
geal cancer (819 of 1280 tumours, (63%) were diagnosed in stages I-II), had better survival
than those with cancers at sites associated with more subtle symptoms, such as the
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hypopharynx. Patients with hypopharyngeal tumours tended to be detected at later stages (293
of 341 tumours (86%) were diagnosed at stages III-IV). If the tumours were discovered later,
patients were at higher risk of early death, findings confirmed elsewhere [28]. Stage IV cancer
had a 3.7 fold risk of death within six months, compared with those with stage I (p<0.001).
Patients with advanced tumours had the shortest survival, independent of the site of the
tumour. In accordance with a number of previous publications [29, 30], our results showed
that advanced tumours and metastatic disease were both associated with an increased risk of
early death. However, there was a significant difference in the risk of early death depending on
the site of the tumour–for example, a patient with hypopharyngeal cancer had a 24% increased
risk compared to patients with tumours in the oral cavity (p<0.024). This is in line with the
results from more than 34 000 patients from Denmark in 2014, among whom the probability
of five-year survival for those with hypopharyngeal cancer was only 22.8% compared with
62.4% for all other sites in the head and neck [31].
Patients being given treatment with curative intent lived longer than those who were given
palliation, who were at a 12-fold risk of death within six months (p<0.001). However, it should
be noted that 223 of patients who had palliative treatment (25%) lived for longer than 12
months, and 104 (14%) for 24 months or more, which is longer than could be expected. This is
particularly interesting as other authors have found that without any treatment the median
survival was usually less than four months [3]. These data suggest that even if the intention of
treatment is not to cure but to palliate, palliative treatment can be effective for a substantial
subgroup, and even prolong time to death.
Patients who were operated on primarily had smaller tumours (1975 of them (87%) had
stage I or II disease). They also had tumours in earlier stages than patients who were treated by
radiotherapy or CRT together with resection, and were therefore more likely to survive. It has
been reported that higher doses of chemotherapy and radiotherapy together with extensive
resection will increase the risk of lethal complications [32]. Patients with advanced cancers of
the head and neck who were admitted to hospital for more than five days during or after radio-
therapy had worse locoregional control, progression-free survival, and overall survival [33].
In the group of patients (n = 245) who were given no active treatment, 89 (36%) had been
recommended for curative treatment at a multidisciplinary tumour board meeting, and 43
(48%) of them died within six months. It could be speculated that these patients chose not to
undergo treatment, were too ill to start, or died before treatment could begin.
For the 1236 patients (12.7%) with missing data about locoregional control at first follow-
up, the mortality within six months was high 493 (40%). At the first check-up after treatment
it can be difficult to decide whether a patient has a residual tumour, or just divergent anatomy/
mucosa after intense treatment. As mortality is so high in this group, clinicians could be more
cautious, and suspect recurrence as soon as there is any doubt.
A limitation of this study was that the actual cause of death is not recorded in the
SweHNCR. It is recorded if the patient is considered to be free of tumour, but the immediate
cause of death is not reported. Questions about whether death was caused by the cancer itself,
by treatment-related complications, coexisting conditions, or causes unrelated to the cancer,
could therefore not be answered by this study. Other limiting factors include the lack of infor-
mation about socioeconomic factors, alcohol consumption, smoking habits, and HPV status,
which were not reported in the SweHNCR until 2015, but thereafter alcohol consumption,
smoking habits, and HPV status have been included. Sawabe et al showed that a high alcohol
consumption leads to significantly shorter overall survival for these patients [34]. Socioeco-
nomic status, other life-style factors, and depression have also been suggested as risk factors
for early death [35–39]. As these data were not reported in the SweHNCR during the study
period, we were unable to evaluate them.
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Smoking is decreasing in Sweden, and roughly 9% of the total population now smoke daily
compared with 15% 10 years ago (according to the Public Health Agency in Sweden). One
could speculate that over time this would result in a decrease in mortality as well. The inci-
dence of HPV-related cancer in the oropharynx is increasing, which can influence and
decrease mortality [40] [41]. However, the large group of patients, its homogeneity in gross
socioeconomic and health-related factors from a well-defined geographical area, and the
degree of coverage of 98.5%, compensate for some of the limiting factors.
We found that older age, advanced stage, and a hypopharyngeal tumour, together with
higher WHO score and palliative treatment were significant risk factors for early death. These
findings contribute to the knowledge of a risk profile for early death among patients with can-
cers of the head and neck, and we think it is important to identify these patients early to opti-
mise treatment, control symptoms, and reduce the number who die early. This study could be
used as a base for future studies of subgroups within the palliative and curative treatment
groups, so that we are able to understand better which patients are at greatest risk of early death.
Taken together, this study indicates that from clinical relevant information, risk profiles
can be identified, and a high-risk patient had a considerable increased risk to die within six
months compared to a low-risk patient. Understanding and identifying high-risk patients for
early death is therefore important for physicians when recommending treatment to patients,
curative or palliative.
Conclusion
We identified a risk profile for early death in this population-based register study of 9733
patients with cancers of the head and neck. The risk depended on patient’s age, WHO score,
site of primary tumour, stage, and intention to treat. Our most important findings were that
the risk of early death increased with 2.3% for every year older the patient became (p<0.001).
The relative risk of death was 3.37 times higher for patients with a WHO score of 1, compared
with a WHO score of 0 (p<0.001). Patients with stage IV disease had a 3.7 times greater risk of
death within six months than those with stage I disease (p<0.001), and the group given pallia-
tive treatment had a 12 times higher risk of early death (p<0.001) than the others. If the
tumour was located in the hypopharynx the risk of dying within six months increased by 24%
compared with that of a tumour in the oral cavity (p = 0.024). Even if the intention of treat-
ment was not cure but palliation, palliative treatment was shown to have an effect for a sub-
stantial group, and possibly prolong time to death.
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